<DOC>
	<DOC>NCT01045187</DOC>
	<brief_summary>Multicenter, non-randomized, feasibility study to evaluate the treatment and assess acute safety of the FDA Cleared Axxent Electronic Brachytherapy System and vaginal applicator for intracavitary vaginal cuff treatment according to the physician's current standard of care.</brief_summary>
	<brief_title>Feasibility Study Using the Xoft System for the Treatment of Endometrial Cancer</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Most types of endometrial (uterine) cancer Stage I and Stage II (see exclusion criteria below) Post hysterectomy Endometrial (uterine) cancer Stage IA Grade 1 Scleroderma Collagen vascular disease Active Lupus</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>endometrial cancer</keyword>
	<keyword>Uterine cancer</keyword>
	<keyword>electronic brachytherapy</keyword>
	<keyword>Xoft</keyword>
</DOC>